News

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 9.5% over the past six months while the S&P 500 was up 6.2%.

Boston Scientific Corporation (NYSE:BSX) is one of the Stocks Expected to Bounce Back According to Analysts. The stock has fallen more than 52% year-to-date, but the Street expects more than 65% upside from the current level. ​Recently, on June 16, TD Cowen analyst Josh Jennings maintained his Buy rating on Boston Scientific Corporation (NYSE:BSX) with […]

In the most recent trading session, Boston Scientific (BSX) closed at $44.46, indicating a -2.5% shift from the previous trading day.

Earlier in June 2026, the US Food and Drug Administration posted a Class II, firm-initiated recall of 9,750 Boston Scientific Orca sterile, single-use air/water and suction valves (lot 38400303, expiring January 20, 2029) after higher-than-expected reports of suction buttons sticking during gastrointestinal endoscopy procedures. The recall, which is ongoing and affects nationwide US distribution, highlights how even accessory devices can create operational and regulatory pressures for a...

Boston Scientific (NYSE:BSX) has initiated a nationwide recall of its Orca Single Use Air/Water and Suction Valves. The recall is voluntary and follows identification of a device malfunction affecting procedures across the United States. The action reflects a material operational event for the company, with implications for patient safety oversight. Boston Scientific is a major medical device company, so a recall tied to endoscopy accessories like the Orca Single Use Air/Water and Suction...

The latest trading day saw Boston Scientific (BSX) settling at $45.6, representing a +2.86% change from its previous close.

While the market fixates on a disruptive quarter for Stryker stock, the company's powerful ability to convert profit into hard cash reveals a deeper, under-appreciated resilience.

Boston Scientific Corp. (NYSE:BSX) is one of the 10 oversold stocks offering high upside. On June 12, Matt O’Brien from Piper Sandler reduced the target price on Boston Scientific Corporation (NYSE:BSX) from $90 to $65, resulting in an adjusted upside potential of close to 45% at the current level. The analyst retained an Overweight rating […]

Boston Scientific Corporation (NYSE:BSX) was among the stocks Jim Cramer discussed as he said that the Iran peace negotiations could trigger an oil glut, cool inflation, and pull interest rates down. A caller asked about Cramer’s thoughts on the stock, and he replied: Now, I gotta tell you something, I was shocked at the decline […]

ISRG raises its 2026 outlook after strong Q1 results, but can broad-based procedure growth offset emerging headwinds in key U.S. and global markets?

According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Boston Scientific Corporation (NYSE:BSX) is one of the most promising healthcare stocks according to Wall Street analysts. On June 4, Truist Securities lowered its price target on Boston Scientific Corporation (NYSE:BSX) from $85 to $64, while keeping its Buy rating on the stock. Richard Newitter, the analyst on record, cited a growing slowdown in demand […]

Medtronic is deeply undervalued and a good bet for your portfolio. At the time, an uncertain growth outlook kept us from recommending the stock. Four months later, it’s time to retire the narrative of Medtronic as a perpetual laggard.

The international launch could benefit from Boston Scientific’s global footprint when the company closes its takeover of Penumbra.

Boston Scientific (BSX) closed the most recent trading day at $44.95, moving 4.2% from the previous trading session.

Renaissance Investment Management, an investment management company, released its Q1 2026 “Large Cap Growth Strategy.” A copy of the letter can be downloaded here. Stocks fell sharply in the first quarter due to the Iran conflict. The Energy and Materials sectors outperformed, Financials and Consumer Discretionary lagged. Large-cap stocks underperformed smaller-cap stocks, and Value outperformed Growth. […]

Deal volumes and values are tracking above the first half of 2025, driven by Boston Scientific’s Penumbra buyout and Danaher’s Masimo acquisition.

Sometimes boring stocks can be the most exciting.

Adobe, Chewy, and Boston Scientific fell to 52-week lows on Friday after receiving multiple price target cuts from Wall Street analysts.

Boston Scientific Corp. (NYSE:BSX) is one of the 12 best buy-the-dip stocks to invest in now. On June 4, Truist significantly decreased the price target on Boston Scientific Corp. (NYSE:BSX), from $85 to $64, while maintaining a Buy rating on the stock. The firm cited recent management remarks indicating that the Watchman device’s growth in […]

Penumbra received FDA clearance for its Thunderbolt stroke thrombectomy device. Boston Scientific (NYSE:BSX) previously agreed to acquire Penumbra, with closing expected later this year. The clearance adds another device to the neurovascular and mechanical thrombectomy portfolio that Boston Scientific is set to own. For investors watching Boston Scientific, the Penumbra deal centers on expanding exposure to neurovascular care and stroke intervention. Thunderbolt now arrives as an FDA...

Analysts remain relatively more upbeat, but this could prove fleeting.

Penumbra’s computer assisted vacuum thrombectomy platform uses aspiration for clot removal during acute ischemic stroke treatment.

The stroke treatment could contribute about $100 million in incremental revenue over time to Boston Scientific, the buyer of Penumbra, one analyst said.

Insightful Moves in Elfun Trusts (Trades, Portfolio)' First Quarter 2026 N-PORT Filing

With a forward P/E of 14.45x and upside potential of 59.60%, Boston Scientific Corporation (NYSE:BSX) ranks among the top 10 lowest forward P/E stocks in the S&P 500. Boston Scientific Corporation (NYSE:BSX) has seen a sharp de-rating in 2026, with shares down nearly 50% year-to-date as of June 8, 2026, even as the vast majority […]

Boston Scientific (BSX) concluded the recent trading session at $48.34, signifying a -1.27% move from its prior day's close.

Boston Scientific Corporation (NYSE:BSX) is one of the best healthcare stocks to buy with highest upside potential. TD Cowen cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $80 on May 29, maintaining a Buy rating on the shares and stating that the firm updated its model to account for the latest Watchman […]

The planned logistics site, near a principal manufacturing facility, will handle global distribution of Boston Scientific’s medical devices.

Boston Scientific Corporation (NYSE:BSX) is one of the oversold stocks to buy right now. On May 18, Boston Scientific entered into an accelerated share repurchase/ASR agreement with JPMorgan Chase Bank to buy back $2 billion of its common stock, part of a previously authorized $5 billion program. The company will immediately receive approximately 30.4 million […]